Sigilon Therapeutics, Inc. is a biopharmaceutical company with a platform of biomedical technologies and cell therapies created to avoid host detection and foreign body responses with a goal of providing functional cures to patients with chronic diseases. The Company has developed its Shielded Living Therapeutics (SLTx) platform, which combines cell engineering in biocompatible materials and enables its product candidates to produce a range of therapeutic molecules, which may be missing or deficient, such as proteins, including therapeutic proteins and antibodies, and hormones. The Company is designing its product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression. Its lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human Factor VIII (FVIII).
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)